Company intelligence / Profile preview

Black Shadow Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Black Diamond Therapeutics is a clinical-stage precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies. The company utilizes its proprietary Mutation-Allostery-Pharmacology (MAP) platform to identify and target oncogenic "master" mutations across various tumor types. Their lead candidate, BDTX-1535, is a fourth-generation EGFR inhibitor targeting a broad spectrum of mutations in non-small cell lung cancer and glioblastoma. Black Diamond aims to address the limitations of current precision medicines by targeting families of mutations rather than single points.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Black Shadow Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Black Shadow Therapeutics.

Explore the full profile